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Background: Age is considered a primary risk factor for neurodegenerative diseases including Alzheimer’s disease
(AD). It is also now well understood that mitochondrial function declines with age. Mitochondrial deficits have been
previously assessed in brain from both human autopsy tissue and disease-relevant transgenic mice. Recently it has
been recognized that abnormalities of muscle may be an intrinsic aspect of AD and might contribute to the
pathophysiology. However, deficits in mitochondrial function have yet to be clearly assessed in tissues outside the
central nervous system (CNS). In the present study, we utilized a well-characterized AD-relevant transgenic mouse
strain to assess mitochondrial respiratory deficits in both brain and muscle. In addition to mitochondrial function,
we assessed levels of transgene-derived amyloid precursor protein (APP) in homogenates isolated from brain and
muscle of these AD-relevant animals.
Results: We now demonstrate that skeletal muscles isolated from these animals have differential levels of mutant
full-length APP depending on muscle type. Additionally, isolated muscle fibers from young transgenic mice
(3 months) have significantly decreased maximal mitochondrial oxygen consumption capacity compared to
non-transgenic, age-matched mice, with similar deficits to those previously described in brain.
Conclusions: This is the first study to directly examine mitochondrial function in skeletal muscle from an
AD-relevant transgenic murine model. As with brain, these deficits in muscle are an early event, occurring prior to
appearance of amyloid plaques.
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A key contributor to disability in Alzheimer’s disease (AD)
besides cognitive deficits is loss of muscle function. Re-
cently it has been recognized that abnormalities of muscle
may be an intrinsic aspect of AD. Studies using MRI of
brain and dual emission x-ray absorptiometry (DEXA)
detection of body mass showed that loss of lean muscle
mass was accelerated in AD and correlated with hippo-
campal atrophy and cognitive performance, with lean
mass independently associated with brain volume [1].* Correspondence: rschu003@umaryland.edu
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stated.Reduced motor function and grip strength are found in
patients with mild cognitive impairment and are risk
factors for later development of AD [2]. Although several
variables including changes in motivation/level of exercise,
depression or unrelated muscle abnormalities could influ-
ence lean muscle mass in this population, these studies
suggest that accelerated loss of lean body mass or develop-
ment of muscle dysfunction could be a component of AD
pathophysiology. A testable hypothesis for the biologic
basis of deficits in both muscle function and cognitive
function in AD is widespread abnormalities in energy me-
tabolism due to mitochondrial dysfunction.
Substantial evidence indicates that mitochondrial func-
tion declines with age, a primary risk factor for AD and
other neurodegenerative diseases (see [3] for review).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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onstrated in AD patients using brain-imaging studies and
has been suggested to occur even prior to onset of clinical
symptoms [4,5]. Mitochondrial-encoded Cytochrome c
oxidase (COX) mRNA levels are reduced in AD postmor-
tem brain tissue and could contribute to reduced brain
oxidative metabolism in AD [6]. COX, pyruvate de-
hydrogenase complex and α-ketoglutarate dehydrogen-
ase complex (KGDH) activities, all critical enzymes for
energy metabolism are reduced in brain of AD patients
[4]. Neurons in layers III and V of the temporal cortex
have been determined to be especially deficient in KGDH
in AD brain [7].
Amyloid deposition, one of the pathologic hallmarks
of AD, is found in tissues outside the CNS [8]. Although
skeletal muscle was initially not found as a site of amyl-
oid deposition, a later study showed detectable amyloid
beta 42 (Aβ42) in skeletal muscle in normal elderly, and
significant evaluations in autopsy AD muscle [9,10].
Skeletal muscle is not the only non-neural tissue where
mitochondrial abnormalities have been associated with
AD. Mitochondrial abnormalities have been well docu-
mented in cybrid systems where platelets containing
mitochondria from AD patients are fused to immortal-
ized cells in culture [11]. Whether such abnormalities
are widespread among tissues is unclear since mito-
chondrial function in lymphocytes of AD patients has
been reported to be normal [12].
Recent studies have also demonstrated mitochondrial
abnormalities in transgenic AD murine models that over-
express human amyloid precursor protein (APP) both in
cells [13-15] and isolated mitochondria [16-19]. Primary
neuronal cultures isolated from Tg2576 mice, a well-
characterized APP murine model of AD had decreased
synaptic proteins and deficits in axonal transport of mito-
chondria. These deficiencies correlated temporally with
accumulation of oligomeric beta amyloid [13]. Utilizing
isolated brain mitochondria from 3 month old mice pos-
sessing two human APP mutations (Swedish and London
mutant APP) [16] demonstrate decreased mitochondrial
membrane potential and reduced ATP levels that corre-
lated temporally with intracellular beta amyloid [16].
Together, these studies suggest that mitochondrial dys-
function precedes extracellular amyloid deposition.
AD transgenic mice including the well studied strain
possessing both a chimeric mouse/human amyloid precur-
sor protein with the Swedish mutations (K595N/M596L)
(APPswe) and a mutant form of presenilin 1 with deletion
of exon 9 (PS1ΔE9) appears to express APP not only in
brain, but in muscle as well (Dr. David Borchelt, personal
communication). Thus, we hypothesized that overexpres-
sion of an AD form of APP, could result in mitochondrial
abnormalities in both tissue types, and testing of this hy-
pothesis could help elucidate the relationship of muscleand cognitive deficits in AD. In addition, we examined the
hypothesis that mitochondrial dysfunction is an early
event that could exacerbate amyloid toxicity predisposing
vulnerable neuronal and non-neuronal cell populations to
degenerate.
We now demonstrate in this double transgenic mouse
strain that skeletal muscles have differential levels of mu-
tant full-length APP depending on muscle type. Isolated
muscle fibers from young mice (3 months) have signifi-
cantly decreased maximal oxygen consumption capacity
compared to non-transgenic, age-matched mice, with simi-
lar mitochondrial deficits to those previously described in
brain. This is the first study to directly examine mitochon-
drial function in skeletal muscle from an AD-relevant
transgenic murine model. As with brain, these deficits in
muscle are an early event, occurring prior to appearance of
amyloid plaques.
Results
Full-length mutant human APP protein levels in both
brain and muscle
Forebrain homogenates were assessed for relative
transgene-derived full-length APP expression in both
APP(swe)/PS1(ΔE9) and non-transgenic mice (3 and
6 months). At 3 months of age, there were increased
human APP levels in the brain homogenates from the
APP(swe)/PS1(ΔE9) mice but this increase was not signifi-
cantly different from their non-transgenic littermates
(Figure 1). There was a significant increase (p < 0.01) in
human APP levels present in brain homogenates from
6 month APP(swe)/PS1(ΔE9) mice as compared to 6 month
non-transgenic littermates (Figure 1).
Although expression of the mutant human gene has
been previously reported in muscle of AD-relevant
transgenic mice [20], such expression has not been
characterized with regard to muscles of varying fiber
type distribution or with age. We examined muscle ho-
mogenates isolated from soleus, plantaris, gastrocnemius
and tibialis anterior muscles in APP(swe)/PS1(ΔE9) and non-
transgenic male mice (3–18 months) for transgene-derived
full-length APP expression as demonstrated in brain tissue
from these animals (Figure 1). Positive immunoreactivity
to 6E10 (which recognizes the N-terminal region of human
Aβ reacting with both abnormally processed forms as well
as precursor forms), was evident in the APP(swe)/PS1(ΔE9)
mice in all ages (3–18 months) tested (Figure 2). Con-
versely, none of the non-transgenic age-matched mice had
positive immunoreactivity to transgene-derived full-length
APP (Figure 2). Soleus had the least APP band intensity,
plantaris had the greatest, with gastrocnemius and tibialis
anterior (TA) APP protein levels falling in between (plan-
taris > TA/gastrocnemius > soleus, Figure 2). This pattern
of band intensities was apparent at all ages tested in the






























 3 mo 
  NTG 
 6 mo 
  NTG 
 3 mo 
  DTG 
 6 mo 
  DTG 
100 Kd 
 45 Kd 
B
A
Figure 1 Full-length, transgene-derived amyloid precursor protein (APP) levels in brain homogenates. (A) Representative Western blots of
homogenates isolated from the brains of App(swe)/PS1(ΔE9) (DTG) and non-transgenic (NTG) male mice (3 and 6 mo) probed with 6E10 antibody.
(B) Transgene-derived, full-length APP (~106 Kd) is observed in DTG mice at both ages tested with negligible levels in the NTG mice. Full-length
APP levels (ratio of APP:β-Actin) are significantly elevated in the 6 mo DTG mice (white bar) compared to NTG (black bar). Data are presented as
the average full-length APP ± SE. N = 3 separate animals per genotype. *p < 0.01.
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Figure 2 Full-length, transgene-derived amyloid precursor
protein (APP) levels in isolated muscle. Representative Western
blots of homogenates isolated from the soleus (sol), plantaris (plan),
gastrocnemius (gast), and tibialis anterior (TA) muscles of App(swe)/
PS1(ΔE9) (DTG) and non-transgenic (NTG) male mice (3–18 mo)
probed with 6E10 antibody. Transgene-derived, full-length APP
(~106 Kd) is observed in DTG mice at all ages tested. There are no
observable bands at this molecular weight in the NTG mice. Within
an age group, there are differences in band intensity of the
full-length APP between the four muscle groups
tested: Plan > TA/Gast > Sol.
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for transgene-derived full-length APP as demonstrated
by Western blotting in both brain and muscle, the re-
mainder of the study focused on this age group.
Oxygen consumption rates (OCR) in isolated brain
mitochondria
To examine the potential relationship between mitochon-
drial respiratory function and amyloid production and de-
position, non-synaptic mitochondria were isolated from
the forebrains of male (3 months) APP(swe)/PS1(ΔE9) mice
and their non-transgenic littermates. There were no sig-
nificant differences in basal oxygen consumption rates
(OCR) between the transgenic and non-transgenic mice
(Figure 3). However, following addition of ADP to initiate
State 3 respiration, the APP(swe)/PS1(ΔE9) mice had
significantly lower OCR (p < 0.01) compared to the non-
transgenic animals (Figure 3). Following oligomycin
addition reducing the rate of O2 consumption to that of
State 4° respiration, there was no significant difference
in OCR between the transgenic and non-transgenic
mice (Figure 3). Further, there was no significant differ-
ence in maximal OCR following addition of carbonyl
Non-transgenic 























Figure 3 Oxygen consumption rates (OCR) in non-synaptic brain mitochondria. Average OCR (pMoles/min) in non-synaptic mitochondria
isolated from App(swe)/PS1(ΔE9) (DTG) and non-transgenic (NTG) male mouse (3 mo) brains. Black bars (NTG) and white bars (DTG). Data are





Figure 4 Oxygen consumption rates (OCR) in isolated single muscle fibers. (A) Average OCR (pMoles/min) in single muscle fibers isolated
from flexor digitorum brevis (FDBs) of App(swe)/PS1(ΔE9) (DTG) and non-transgenic (NTG) male mice (3 mo). Solid black line (NTG) and dotted line
(DTG). (B) Graphical presentation of traces in (A). Black bars (NTG) and white bars (DTG). Data are presented as the average OCR ± SE. N = 3-5
separate animals per genotype. *p < 0.01. Arrows represent successive additions of oligomycin (1 μg/ml), FCCP + pyruvate (400 nM + 10 mM
respectively), and antimycin A (1 μM).
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the APP(swe)/PS1 (ΔE9) transgenic mice as compared to the
non-transgenic animals (Figure 3).
Oxygen consumption rates (OCR) in isolated single
muscle fibers
To begin assessment of mitochondrial respiratory deficits
in skeletal muscle, we utilized a technique recently devel-
oped [21]. Individual muscle fibers isolated from the flexor
digitorum brevis muscles (FDBs) of male APP(swe)/
PS1(ΔE9) transgenic and non-transgenic mice (3 months)
were examined for deficits in oxygen consumption. Unlike
isolated mitochondria, addition of external ADP would
have no effect on the internal ADP levels in the intact
FDBs, thus requiring FCCP which is membrane perme-
able, to stimulate respiration. There were no significant




Figure 5 Localization of mitochondrial EYFP and APP in C2C12 myotu
Material and Methods) then incubated with mitotracker (red, left panel) or
yellow fluorescent protein (EYFP) is in green and co-localizes with mitotrac
Representative OCR (pMoles/min) for transfected C2C12 myotubes (left pan
Average OCR (pMoles/min) for 3 separate cultures (right panel). Black bars
the average OCR ± SE. Arrows represent successive additions of oligomycin
antimycin A (1 μM).transgenic mice (Figure 4). Further, following oligomycin
addition there was no difference in OCR between the two
groups (Figure 4). However, the APP(swe)/PS1(ΔE9) had
significantly lower (p < 0.01) maximal OCR following
addition of the uncoupler FCCP as compared to the
non-transgenic mice. These mitochondrial deficits are
present at an age when appearance of amyloid plaques
are not yet observed in the brain [22] and recapitulate
the respiratory deficits observed in brain mitochondria
from these animals (Figure 3).
Mutant APP and mitochondrial eYFP localization in C2C12
cells
As confirmatory studies to examine if mitochondrial re-
spiratory function is affected by expression of the mu-
tant transgenes in our AD mice, we created a construct
containing the same mutant APP(swe) and PS1(ΔE9) DNAAPP eYFP
DAPI
bes. (A) Cells were co-transfected with DNA constructs (described in
APP antibody (red, right panel) and dapi (blue). The enhanced
ker (left panel) but not APP (right panel). (Magnification 40x). (B)
el). Solid black line (Control cells) and dotted line (Transfected cells).
(Control cells) and white bars (Transfected cells). Data are presented as
(1 μg/ml), FCCP + pyruvate (400 nM + 200 μM respectively), and
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fluorescent protein (EYFP) possessing a mitochondrial tar-
geting sequence and a tetracycline response element. To
assess localization of our gene of interest, we transiently
co-transfected C2C12 myoblasts with our construct plus
one containing a tetracycline-controlled transactivator,
then performed co-localization studies using mitotracker
red (Figure 5A, left panel) and immunostaining with α-
APP antibody (Figure 5A, right panel). The EYFP com-
pletely co-localized with mitotracker red confirming its
mitochondrial localization (Figure 5A, left panel). Con-
versely, the APP did not co-localize with the EYFP suggest-
ing a cytosolic localization (Figure 5A, right panel). We
then assessed whether transient transfection of the C2C12
myotube cultures affected mitochondrial respiratory func-
tion. Similarly to the isolated muscle fibers (Figure 4), there
were no differences in basal OCR or following oligomy-
cin addition between the transfected cells and control
















































Figure 6 Oxygen consumption rates (OCR) in transfected single musc
isolated from flexor digitorum brevis (FDBs) of C57/BL6 wildtype male mice
(Transfected fibers). (B) Average OCR (pMoles/min) of single muscle fibers i
(Contralateral control fibers) and white bars (Transfected fibers). Data are pr
represent successive additions of FCCP + pyruvate (400 nM + 10 mM respecaddition of the uncoupler FCCP was decreased in the
transfected cells (~ 22%) when compared to the control
cells (Figure 5B).Electroporation of mutant APP and PS1 in wildtype
mouse footpads
Utilizing the same DNA constructs as transfected into the
C2C12 cells, the footpads of young C57/BL6 wildtype mice
(3 months) were electroporated with either both constructs
(right footpad) or a single construct (left footpad) as a
contralateral control. The single fibers isolated from FDBs
were assessed for OCR with those isolated from the right
footpads having a decrease in OCR following maximal
stimulation with FCCP (Figure 6) as compared to the
contralateral control fibers (Figure 6). Additionally, this
decreased OCR recapitulated what was demonstrated in
the fibers isolated from our APP(swe)/PS1(ΔE9) transgenic







le fibers. (A) Representative OCR (pMoles/min) for single muscle fibers
(3 mo). Solid black line (Contralateral control fibers) and dotted line
solated from FDBs of C57/BL6 wildtype male mice (3 mo). Black bars
esented as the average OCR ± SE. N = 2 separate animals. Arrows
tively), and antimycin A (1 μM).
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In spite of the growing interest in the impact of Alzheimer’s
disease (AD) on tissues outside the nervous system,
our current study is the first evaluation of mitochon-
drial respiratory function in a non-neural tissue such as
muscle in an AD relevant transgenic model mouse
strain. We have not only confirmed that the widely uti-
lized APP(swe)/PS1(ΔE9) strain expresses the full length
transgene in skeletal muscle, but that this expression is
readily detectable at an early age (3 months), compar-
able to that seen in brain.
As with brain, transgenic APP expression in muscle
increases with age. A recent study by [20] with young
mice (1–2 months) possessing a whole body knock-in of
human APP/PS1 is the only previous study where any as-
pect of APP expression in muscle has been previously
assessed in an AD relevant transgenic animal. This study
detected increased amyloid beta (Aβ) and C-terminal frag-
ment of APP (CTFβ) in brain and quadriceps muscle, and
attempted unsuccessfully to lower these levels with a keto-
genic diet [20].
Muscles containing different degrees of fiber type
composition appear to express varying levels of full-
length mutant APP in our transgenic animals. The low-
est band intensity for full-length APP was apparent in
homogenates from soleus muscles that are comprised
mostly of slow twitch fibers, (i.e. type I fibers), [23]. Con-
versely, the plantaris, comprised mainly of fast twitch fi-
bers (i.e. type II fibers), had the most intense full-length
APP bands. The full-length mutant APP band intensities
for the gastrocnemius and tibialis anterior muscles (both
comprised of a mix of slow and fast twitch fibers) had
intermediate levels.
In the present study, we demonstrate that our APP(swe)/
PS1(ΔE9) transgenic mice have reduced mitochondrial oxy-
gen consumption rates (OCR) in intact single fibers iso-
lated from their FDBs when challenged with uncoupler
(FCCP). These deficits in OCR were demonstrated in 3-
month animals, an age already determined to precede
amyloid deposition and plaque formation in brain [22].
Mitochondrial dysfunction has been reported previously
in brain from several strains of AD-relevant transgenic
mouse models [16,17,19,24]. Our examination of mito-
chondria isolated from brain (Figure 3) in this well-
characterized animal model of AD is in agreement with
these findings and further implies that mitochondrial
dysfunction precedes amyloid deposition. Interestingly,
differences in AD-relevant transgenic mouse strains may
result in altered temporal presentation of mitochondrial
deficiencies. Utilizing mice overexpressing two human
mutant forms of APP, [25] demonstrated deficient mito-
chondrial oxygen consumption in synaptic but not non-
synaptic mitochondria isolated from brains of 4 month
mice. These deficits in non-synaptic mitochondria becameapparent only at 12 months of age. This is not in agree-
ment with our present findings in which we had signifi-
cant decrease in oxygen consumption in non-synaptic
mitochondria isolated from brains of (3 month) transgenic
mice (Figure 3). This disparity could be due to mutant
PS1 in our mice that is not expressed in animals in the
other study [25]. Although the majority of evidence sug-
gests that the primary effect of PS1 mutation is through
the enhancement of amyloid production it does not ad-
dress the issue of whether this effect (on mitochondria) is
independent of the effect of PS1 on amyloid generation.
There are limited studies assessing mitochondrial deficien-
cies in transgenic mouse strains possessing mutant PS1
expression only.
Utilizing lymphocytes and liver mitochondria from mice
possessing a single PS1 mutation (M146L) or five distinct
mutations related to familial AD [26] determined that
ROS levels were increased and calcium regulation altered
but no changes observed in mitochondrial cytochrome c.
A later study [27] utilizing mice with the single PS1 mu-
tation [26] determined that lipid peroxidation and mito-
chondrial ROS levels were increased in brains from
elderly animals (19–22 month). These deficiencies were
not however observed in younger (3 month) transgenic
mice. Since these mice and other PS1 strains do not de-
velop amyloid plaques in brain tissue with aging, the
authors suggest that Abeta is not required to initiate
oxidative damage [27]. Interestingly, differential effects
are observed when mouse strains possessing alternative
Presenilin mutations are utilized. Mitochondrial mem-
brane potential was differentially deficient in embryonic
fibroblasts and mitochondria isolated from mice with
PS1 or PS2 mutations but all had competent bioener-
getic function [28].
Although metabolic failure due to mitochondrial dys-
function appears to be an early event in the pathophysi-
ology leading to AD, amyloid toxicity may still play a
central role in the neurodegenerative decline associated
with AD. Currently the relationship of amyloid gener-
ation and toxicity to mitochondrial dysfunction in the
brain is still unclear, with evidence for both a role of
amyloid toxicity leading to mitochondrial abnormalities
as well as a role for mitochondrial dysfunction exacerbat-
ing amyloid generation and toxicity [29]. Several studies
have demonstrated that both full-length amyloid precur-
sor protein (APP) [30] as well as beta amyloid (A-beta,
Aβ) [31] accumulates in brain mitochondria from autopsy
tissue of AD patients but not in age-matched controls.
APP accumulation in mitochondrial import channels of
human AD patients was associated with import inhibition
of nuclear-encoded subunits of COX with subsequent de-
crease in COX activity and increased hydrogen peroxide
levels [30]. APP accumulation was especially apparent in
AD-vulnerable brain regions including hippocampus and
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is present in brain mitochondria from transgenic mice
with targeted neuronal overexpression of mutant human
amyloid precursor protein. The progressive mitochondrial
accumulation of Aβ was associated with diminished en-
zyme activity of electron transport chain complexes III
and IV and reduced oxygen consumption. Detection of
mitochondria-associated Aβ was an early event occurring
prior to extracellular Aβ deposits [24]. We now demon-
strate that transgene-derived APP effects on mitochon-
drial function occur quite rapidly. In both C2C12
myotubes or single fibers isolated from the FDB of young,
wildtype mice (following cDNA electroporation) even
transient transfection of the APP(swe)/PS1(ΔE9) transgenes
gives rise to similar OCR deficits as found in our trans-
genic mice.
Although this is the first report of mitochondrial ab-
normalities in muscle from an AD relevant transgenic
mouse model, its result are not unexpected on the basis
of related previous studies. Amyloid deposits consisting
of the Aβ42 peptide (identical to that in AD) occur also
in muscle in patients with the age related muscle disease
inclusion body myositis (IBM) [32]. Mitochondrial ab-
normalities including deficiencies in cytochrome C oxi-
dase activity, structural defects and mitochondrial DNA
deletions have also been described in muscle from IBM
patients [33-35]. Askanas et al., [36] also demonstrated
similar mitochondrial abnormalities in normal human
muscle cultures following adenovirus-mediated βAPP
gene transfer. In another effort to model the pathophysi-
ology of human IBM, a transgenic mouse with muscle-
specific expression of the APP(swe) mutation has been
created [37]. A recent study by Boncompagni et al., [38]
demonstrated that muscle isolated from these mice also
have mitochondrial abnormalities as determined by elec-
tron microscopy, altered TCA cycle activity and an al-
tered redox state.
Although abnormalities of muscle may be an intrinsic
aspect of AD, they have not yet been well explored. A
reasonable working hypothesis for the biologic basis of
a relationship of muscle function to cognitive function
in AD is widespread abnormalities in energy meta-
bolism due to mitochondrial dysfunction. Our study
supports the hypothesis that overexpression of a patho-
genic form of APP can result in defects in oxidative me-
tabolism both in brain and muscle, and that these
defects are evident at an early stage in the disease, prior
to the formation of amyloid plaques in typical brain re-
gions [22].
The known abnormalities in mitochondrial function in
AD provide another potential target for disease modifying
therapy of AD that is related to, but distinct from, current
anti-amyloid based strategies. Interest in abnormalities in
more accessible non-neural tissues in neurodegenerativediseases such as AD have commonly been motivated by
their potential utility as disease biomarkers [39].
Conclusions
Our demonstration that overexpression of pathogenic
APP can result in quantifiable abnormalities in oxidative
respiration in both brain and muscle of a transgenic
mouse model of AD, raises the possibility that similar
abnormalities exist in both brain and muscle of patients
with even early stages of AD. Further studies of AD pa-
tient derived cells and tissue will be needed to determine
if similar metabolic abnormalities occur as have been
shown in this animal model study. A combined approach
measuring mitochondrial bioenergetics from brain and
non-neural tissue such as muscle from transgenic mouse
models of AD, along with non-neural tissue from patients
with AD could define and validate these physiologic ab-
normalities. Such an approach could serve an important
role in the assessment of promising AD therapeutic agents
based on enhancing mitochondrial function.
Methods
Chemicals
All chemicals were purchased from Sigma-Aldrich (St
Louis, MO) unless otherwise stated.
Animals
Double transgenic mice expressing a chimeric mouse/hu-
man amyloid precursor protein (APP) with the Swedish
mutation (APPswe) and a mutant human presenilin 1
(PS1) with the delta E9 (PS1ΔE9) (strain # 005864) and
wildtype C57BL/6 mice were purchased from the Jackson
Laboratory, (Bar Harbor, ME). Male mice (3–18 months)
were used in this study to avoid estrogen-related con-
founders. The University of Maryland School of Medicine
Institutional Animal Use and Care Committee approved
all procedures involving animal care, euthanasia and tissue
collection.
Genotyping
Animals positive for the transgenes were identified by
PCR using genomic DNA, isolated from the tails (Qiagen,
Valencia, CA). The primer sequences for genotyping the
mice were (APP) forward 5′-GACTGACCACTCGACC
AGGTTCTG-3′, and reverse 5′-CTTGTAAGTTGGAT
TCTCATATCCG-3′ to amplify a 350 bp fragment; (PS1)
forward 5′-AATAGAGAACGGCAGGAGCA-3′ and re-
verse 5′-GCCATGAGGGCACTAATCAT-3′ to amplify a
608 bp fragment. One hundred nanograms of genomic
DNA were used in the PCRs, with a program of one cycle
of 95°C for 3 min, 33 cycles of 95°C for 45 s, 62°C for 45 s
and 72°C for 45 s, and one cycle of 72°C for 5 min. The
PCR products were separated on a 1% agarose gel, stained
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Imager (Bio-Rad, Hercules, CA).
Isolation of non-synaptic brain mitochondria
After decapitation, forebrain was rapidly removed from
APP(swe)/PS1(ΔE9) or non-transgenic male mice (3 months)
and placed in ice-cold mannitol-sucrose (MS) buffer
pH 7.4 (225 mM mannitol, 75 mM sucrose, 5 mM
Hepes, 1 mg/ml fatty acid free BSA (Roche Diagnostics,
Indianapolis, IN), 1 mM EGTA). Forebrains were ho-
mogenized with 10 strokes using a Potter-Elvehjem tis-
sue grinder (Wheaton Science Products, Millville, NJ).
The brain homogenates were further processed using
the Percoll isolation method described by [40] and as
used previously [41] with slight modification. Briefly, the
brain homogenate was centrifuged twice at 1,317 × g for
3 min. The collected supernatant was further centri-
fuged for 10 min at 21,074 × g and the resulting pellet
resuspended in 15% Percoll (Amersham Biosciences,
Piscataway, NJ) then layered on a discontinuous 40%
and 24% Percoll gradient and spun at 29,718 × g for
8 min. The non-synaptic mitochondrial fraction was re-
suspended in MS buffer then centrifuged at 16,599 × g
for 10 min. The mitochondrial pellet was resuspended
in MS buffer containing 1 mg/ml fatty acid free BSA
(Roche) then spun at 6,668 × g for 10 min. The mito-
chondrial pellet was resuspended in a small volume of
MS buffer (minus EGTA) after removal of the super-
natant following the final spin. Protein concentrations
were determined by the method described by [42] using
BSA as standards. Aliquots of brain homogenate had pro-
tease inhibitors (Calbiochem, San Diego, CA) added prior
to storage at −80°C for later Western blot analyses.
Single fiber isolation
Flexor digitorum brevis (FDB) muscles were harvested
bilaterally from APP(swe)/PS1(ΔE9) or non-transgenic male
mice (3 months). The isolation procedure was then per-
formed as previously described [21]. Additionally, soleus,
plantaris, gastrocnemius and tibialis anterior muscles were
harvested from these same mice as well as from APP(swe)/
PS1(ΔE9) or non-transgenic male mice (6 and 18 months).
These muscles were snap frozen in liquid nitrogen and
stored at −80°C for later Western blot analyses. The indi-
vidual muscles for Western blotting were homogenized
utilizing a BulletBlender (Next Advance, Averil Park, NY)
according to the manufacturer’s protocol.
C2C12 cell culture conditions
Low passage C2C12 myoblasts (ATCC, Manassas, VA;
25,000/well) were seeded on V7 microplates (Seahorse
Bioscience, North Billerica, MA) in proliferation media
((DMEM, (ATCC), 10% fetal bovine serum, (Gibco, Grand
Island, NY), 1% Pen-Strep, (Gibco)) and maintained in ahumidified incubator at 37°C and 5% CO2. After 24 hours,
cultures were transiently transfected (see below). After a
further 24 hours, the proliferation media was replaced
with differentiation media (DM) consisting of DMEM, 2%
horse serum (Gibco) and 1% Pen-Strep. The cultures had
media changes using DM every other day until the myo-
tubes covered each well in the plate. All wells were critic-
ally examined under the microscope to ensure adequate
myotubes formation, with plates being used when myo-
tubes were completely covering the plate (~ 7 days after
seeding).
Plasmid vector generation and transfection
cDNA for enhanced yellow fluorescent protein possessing
a mitochondrial targeting sequence (mEYFP) [43] was
inserted into a pTRE-Tight-BI plasmid vector (Clontech,
Mountain View, CA). Downstream of the mEYFP a 2A
DNA sequence [44] and mutant PS1(ΔE9) were inserted.
Mutant APP(swe) was inserted into the vector in the op-
posite direction. (APP(swe)/PS1(ΔE9) cDNA kind gift from
Dr. David Borchelt). This construct possesses a tetracyc-
line response element thus requiring co-transfection with
a tetracycline transactivator (TTA, Clontech) giving rise
to cells possessing EYFP targeted to mitochondria and
transgene-derived APP and PS1. C2C12 myoblasts were
co-transfected with both constructs utilizing 2 μg of
DNA/construct/well using lipofectamine (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol.
Immunoblotting
Proteins as determined by [42] from mouse muscle (50 μg)
and brain (20 μg) homogenates of APP(swe)/PS1(ΔE9) and
their non-transgenic litter mates (3–18 months) were re-
solved using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) on 4-15% precast Mini-
Protean TGX gels (Bio-Rad) and transferred to a polyvi-
nylidene difluoride membrane using a Trans-Blot Turbo
transfer system (Bio-Rad). Immunoblotting was per-
formed according to Li-Cor Biosciences (Lincoln, NE)
protocol. Briefly, nonspecific sites were blocked in non-
mammalian blocking buffer (Li-Cor Biosciences). Mem-
branes were then incubated at 4°C overnight in mouse
anti-human A-beta (Aβ) monoclonal antibody (6E10,
Covance) at 1:500 dilution that detects transgene-derived
full-length APP at ~100 kD [45] and lower molecular
weight amyloid peptides. After 4 × 5 min washes in tris
buffered saline (TBS), the membranes were incubated with
anti mouse secondary antibody conjugated to IR green at
1:5,000 dilution (Li-Cor Biosciences). The infrared signal
was captured on an Odyssey infrared imaging system (Li-
Cor Biosciences) and stored as a digital image. The mem-
branes were then stripped with stripping buffer and
reprobed with rabbit anti-GAPDH (Cell Signaling Tech-
nology, Danvers, MA) monoclonal antibody at 1:20,000
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jugated to IR red at 1:50,000 dilution (muscle); or rabbit
anti β-Actin (Cell Signaling Technology) monoclonal anti-
body at 1:1,000 dilution (brain) and anti-rabbit secondary
antibody conjugated to IR red at 1:20,000 dilution (brain)
to ensure equal loading.
Immunocytochemistry
C2C12 myoblasts were plated on poly-L-lysine coated
cover slips in 24-well culture plates (Corning, Lowell,
MA) in proliferation media (see above) and maintained
in a humidified incubator at 37°C and 5% CO2. After
24 hours, cultures were transiently transfected as de-
scribed above. The following day, cells were incubated
for 30 min with MitoTracker Red CMXRos (Molecular
Probes, 200 nM) a cell-permeant probe that will accu-
mulate in active mitochondria. Cells were fixed in 4%
paraformaldehyde for 5 min, washed in PBS and mounted
on slides. A separate group of transfected myoblasts
plated on coverslips were fixed as above then incubated in
rabbit anti-APP polyclonal antibody (Cell Signaling Tech-
nology) at 1:50 dilution and anti-rabbit conjugated to
Alexa Fluor 594 secondary antibody (Invitrogen) at 1:500
dilution according to the manufacturer’s protocol. Cell
fluorescence was captured utilizing an AxioCam MRM
monochrome charge-coupled device (CCD) camera and
detected with a Zeiss Axio Observer Z1 with ApoTome
(Zeiss, Thornwood, NY) using Axiovision software (Zeiss).
Brain Mitochondrial respirometry
Following calibration of the Seahorse XF24-3 flux analyzer
(Seahorse Bioscience), the final non-synaptic mitochon-
drial pellets from individual mouse brains were resus-
pended in MAS1 buffer [46] pH 7.2 (70 mM sucrose,
220 mM D-mannitol, 5 mM KH2PO4, 5 mM MgCl2,
2 mM Hepes, 1 mM EGTA, 0.2% fatty acid free BSA
(Roche)) and 5 μg protein as determined above [42]
loaded into each of 20 wells of an XF24 V7 cell culture
plate (Seahorse Bioscience). The plates were centrifuged
at 1,600 × g at 4°C for 5 min. MAS1 buffer with 5 mM L-
malate plus 5 mM sodium pyruvate (freshly made in
MAS1 buffer) was gently added to the wells and the plates
immediately loaded onto the instrument and oxygen con-
sumption measurements were recorded. The experimental
measurements consisted of cycle 1 (1 min mix, 1.5 min
wait, 0.5 min mix, 2 min measure, 1 min mix) prior to in-
jection of ADP (4 mM). Then cycle 2 (0.5 min mix, 2 min
measure, 1 min mix) followed by injection of oligomycin
(2.5 μg/ml). Following oligomycin addition, cycle 2 was
repeated then carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP, 4 μM) was injected. A final
0.5 min mix and 2 min measure was performed prior to
termination of the experiment. Reagent concentrations
were chosen based on previous experiments utilizingisolated mitochondria measured with the Seahorse XF24
[46]. All measurements were performed at 37°C.
Individual, intact muscle fiber respirometry
Bioenergetic analyses were performed utilizing an XF24-
3 Seahorse Extracellular Flux Analyzer (Seahorse Bio-
Science). The procedure was performed as previously
described [21] with modifications. Specifically, prior to
measurements, pre-warmed (37°C) assay measurement
buffer (MB) consisting of 120 mM NaCl, 3.5 mM KCl,
1.3 mM CaCl2, 0.4 mM KH2PO4, 1 mM MgCl2, 5 mM
HEPES (pH 7.4) supplemented with 2.5 mM D-glucose
and 0.5 mM L-carnitine was gently added to the fibers.
The fibers were then placed in an unbuffered, humidified
incubator at 37°C for 2 hours to allow temperature and
pH equilibration. Fibers were visually inspected prior to
and after MB addition then loaded onto the instrument.
After an equilibration step, basal oxygen consumption
rates (OCR, pMoles/min) were recorded using 3-min mix,
2-min wait, and 3-min measure (looped 3 times) cycles
prior to injection of oligomycin to inhibit the ATP syn-
thase. Three more measurement loops were recorded
prior to injection of substrate plus FCCP to induce max-
imal oxygen consumption. Following recording of 3 more
measurement loops, antimycin A (inhibitor of mitochon-
drial respiration) was injected to assess non-mitochondrial
OCR. Two measurement loops were recorded after anti-
mycin A injection then the experiment was terminated.
The injectates prepared in MB (75 μl volumes) were pre-
loaded, then sequentially injected as indicated through
ports in the XF24 calibration cartridge to final concentra-
tions of 1 μg/ml oligomycin, 400 nM FCCP + 10 mM
pyruvate, and 1 μM antimycin A.
Electroporation
Both DNA constructs described above were injected
into the right footpad of male wild type C57BL/6 mice
(3 months). As a contralateral control, the left footpad
received only one of the constructs. The feet were elec-
troporated as previously described [47] and the FDBs
harvested (as described above) one week later. Follow-
ing isolation, the individual intact fibers were seeded on
a V7 microplate (Seahorse Bioscience) for respirometry
measurements as detailed above but without oligomycin.
C2C12 myotube respirometry
Prior to measurements, cultures were gently rinsed in pre-
warmed (37°C) MB (see above) then placed in a 37°C hu-
midified, unbuffered incubator for 2 hours to allow for
temperature and pH equilibration. Myotubes were visually
inspected prior to and after MB addition then loaded onto
the instrument and the experimental procedure was per-
formed as above with the FDBs.
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Data are expressed as means ± SE, and the comparisons
between experimental groups were made with SPSS stat-
istical software (SPSS, Inc., Chicago, IL) using analysis of
variance (ANOVA). Posthoc Holm-Sidak method was
used for all pairwise comparisons after ANOVA tests.
Significance was assumed at p < 0.05.
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